In a challenging year for biotechnology firms, PureTech Health PLC (PRTC) stock has touched a 52-week low, dipping to $16.81.

PureTech has presented data demonstrating high expression of galectin-9 across various solid tumor types and blood cancers and has found that, in several cancers, galectin-9 levels correlate with ...

The two doses of deupirfenidone were chosen based on PureTech’s Phase 1 data, which showed that a 550 mg TID dose of deupirfenidone provided approximately equivalent drug exposure to pirfenidone ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks An announcement from PureTech Health ( (GB:PRTC)) is now available. PureTech Health announced promising results ...

Boston-situated clinical-stage biotherapeutics company PureTech’s Phase IIb trial of deupirfenidone met all primary and secondary endpoints, slowing lung degeneration in patients with idiopathic ...

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and ...

Check the time stamp on this data. Updated AI-Generated Signals for Puretech Health Plc (PRTC) available here: PRTC. Type a ...

When you crunch the numbers, however, the PureTech petrol DS 4 just doesn’t offer a compelling enough package, as a company car, to sit above its premium rivals like the Audi A3 and BMW 1 Series.

LYT-200 exerts its therapeutic effects in AML by killing cancer cells directly via apoptosis and DNA damage as well as reactivating central anti-cancer effectors of the immune system. LYT-200 is the ...